PATENT OWNER'S UPDATED EXHIBIT LIST

Exhibit No.	Description
2001	International Nonproprietary Names for Pharmaceutical Substances, WHO Drug Information, Vol. 38, No. 2, 2024
2002	Fei Han et al., Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study
2003	Lepu Biopharma Co., Ltd., Voluntary Announcement, Breakthrough Therapy Designation Granted by the FDA to MRG003 for the Treatment of R/M NPC
2004	U.S. Food & Drug Administration, Fast Track
2005	U.S. Food & Drug Administration, Breakthrough Therapy
2006	EGFR expression in normal human tissues (HPA RNA-seq normal tissues) - https://www.ncbi.nlm.nih.gov/gene/1956
2007	CD30 expression in normal human tissues (HPA RNA-seq normal tissues) - https://www.ncbi.nlm.nih.gov/gene/943
2008	European Patent Application No. EP4434549A1
2009	CSPC Pharmaceutical Group Limited Voluntary Announcement, May 19, 2025
2010	Lu S. et al., "Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors," Cancer Res (2025) 85 (8_Supplement_2): CT008
2011	International Publication No. WO2012/100346A1
2012	Huang L. et al., "Abstract 1217: Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors," *Cancer Res.* (2016) 76 (14_Supplement): 1217

2013	Phillips AC et al., "Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate," *Mol Cancer Ther*; 17(4) April 2018 795-805
2014	Carneiro B. et al., "Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma," *Neuro-Oncology Advances* 5(1), 1–12, 2022
2015	U.S. Patent Application Publication No. 2011/0076232 ("Old-232")
2016	AbbVie, A Study Evaluating Safety and Pharmacokinetics of ABB-221 in Subjects with Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor. ClinicalTrials.gov Identifier NCT02365662 (March 30, 2018)
2017	Lepu Biopharma Co. Ltd. 2024 Annual Report
2018	Written Opinion of the International Searching Authority for WO2023/088382
2019	Conference Transcript for Proceedings on December 2, 2025
2020	Bournazos S et al., "Signaling by Antibodies: Recent Progress," *Annu Rev Immunol.* 2017 Apr 26; 35:285-311. doi: 10.1146/annurev-immunol-051116-052433. PMID: 28446061; PMCID: PMC5613280
2021	Lepu Biopharma Co. Ltd. 2024 Inside Information Announcement
2022	Crombet T., et al., "Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination with Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients," *Journal of Clinical Oncology* 22(9):1646-1654, 2004
2023	Garrido G. et al., "Bivalent binding by intermediate affinity of nimotuzumab, A contribution to explain antibody clinical profile," *Cancer Biology & Therapy* 11:4, 373-382; 2011 (Garrido)
2024	Abdullah S. et al., "Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management," *Chemother Res Pract*. 2012 Sep 11; 2012:351210

2025	Burke P. et al., "Design, Synthesis, and Biological Evaluation of Antibody−Drug Conjugates Comprised of Potent Camptothecin Analogues," *Bioconjug Chem*, 2009 Jun;20(6):1242-50
2026	Deposition Transcript of Dr. Stylianos Bournazos
2027	Declaration of Dr. Djordje Atanackovic
2028	ClinicalTrials.gov webpage for clinical trial NCT01741727 (downloaded from https://clinicaltrials.gov/study/NCT01741727 on January 19, 2026)
2029	Phillips A.C., et al., "ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope," *Mol Cancer Ther* (2016) 15 (4): 661–669
2030	Yu J. et al., "Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers," Front. Mol. Biosci., 27 February 2022;9:847835. doi: 10.3389/fmolb.2022.847835
2031	ClinicalTrials.gov webpage for clinical trial NCT06927986 (downloaded from https://clinicaltrials.gov/study/NCT06927986 on January 19, 2026)
2032	Lepu Biopharma Co., Ltd., Stock Code: 2157, "Global Offering" dated February 10, 2022
2033	CSPC Pharmaceutical Group Limited, 2020 Annual Report
2034	Assignment Record including Absorption Merger Agreement, Notice of Approval for Deregistration, and their certified English translations